The largest meta-analysis to date, comprising 13 cardiovascular outcome trials involving 83,258 patients with and without diabetes, confirmed that GLP-1 Ras significantly reduced major adverse cardiovascular events (MACEs), all-cause mortality, cardiovascular mortality, fatal and non-fatal strokes, coronary revascularization, and composite kidney outcomes [87]. This evidence concerns the gene GCG and diabetes mellitus.